Stacking DHT Derivatives (Primo/Mast) & The Worst PED Invented | UK PRO MUSCLE Podcast Episode 2

1:32 – 10:29

Why DHT derivatives matter, even when you do not feel them

The conversation opens with a frustration almost every enhanced athlete has seen: people judging a compound by how hard it hits their nervous system instead of what it does to actual muscle growth. Kuba points out that many lifters love nandrolone or tren ace because they feel them immediately, more water, more leverage, more aggression, more “oomph.” Michael Coe cuts straight through that logic: “You won't feel muscle growth.” In his view, many athletes are not addicted to results, they are addicted to the feeling of side effects. From there, he builds the physiology. Testosterone can be converted into DHT by the 5-alpha reductase enzyme, but muscle tissue has a problem: it does not meaningfully express that enzyme. So inside the muscle cell, your own testosterone is not becoming DHT. That matters because DHT has major advantages over testosterone. Michael says it binds the androgen receptor “4 to 10 times” more strongly, stays attached longer, and, most importantly, helps increase the expression of new androgen receptors. His point is that DHT is not just another androgen. It can create a positive feedback loop, more receptor activity, then more opportunity for future signaling. That leads to the reason compounds like Masteron and Primobolan were developed. Natural DHT gets inactivated quickly by an enzyme called 3 alpha hydroxysteroid dehydrogenase. Scientists modified the molecule so derivatives like drostanolone and methenolone could resist that inactivation and keep working in muscle tissue. That is the unexpected angle of the whole episode: these drugs were not magical bro compounds discovered by gym folklore. They were chemical solutions to a very specific biological limitation. Kuba then raises a claim that gets repeated online all the time, that Masteron or Primo are weak and do not build much muscle. Michael's response is sharp: “They're right. On paper.” But only because drostanolone was never really studied as a muscle builder. It was introduced as a treatment for estrogen-induced breast cancer in women, so there was no research incentive to prove anabolic effects in the way bodybuilders want. In other words, lack of studies became internet proof of lack of effect. Michael's argument is that this is a category error, not evidence.